Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effects of Dry Needling on Latent Myofascial Trigger Points of the Extensor Digitorum Communis

NCT07672093 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-07-01
Last updated
2026-09-24

Condition(s) studied

Dry Needling TechniqueTrigger Point PainPhysical Therapy

Investigational drug(s) / intervention(s)

Hong fast-in and fast-out dry needlingRotational dry needlingBipolar electrical dry needlingMonopolar electrical dry needling

Hong fast-in and fast-out dry needling: The skin will be disinfected with 0.5% alcoholic chlorhexidine. With the participant in supine position, a sterile needle will be inserted into the latent myofascial trigger point of the extensor digitorum muscle. Once the needle has reached the trigger point, 10 fast-in and fast-out movements will be performed. The number of local twitch responses will be recorded.

Rotational dry needling: The skin will be disinfected with 0.5% alcoholic chlorhexidine. With the participant in supine position, a sterile needle will be inserted into the latent myofascial trigger point of the extensor digitorum muscle. Once the needle has reached the trigger point, the rotational dry needling technique will be applied according to the predefined study protocol.

Bipolar electrical dry needling: The skin will be disinfected with 0.5% alcoholic chlorhexidine. With the participant in supine position, a sterile needle will be inserted into the latent myofascial trigger point of the extensor digitorum muscle. Once a local twitch response has been obtained, the needle will remain inserted and will act as the negative pole. An adhesive electrode connected to the positive pole will be placed approximately one centimeter from the needle. A TENS current will be applied for 15 minutes at a frequency of 2 Hz and a pulse width of 120 milliseconds. The intensity will be increased until visible, non-painful contractions of the extensor digitorum muscle are achieved.

Monopolar electrical dry needling: The skin will be disinfected with 0.5% alcoholic chlorhexidine. With the participant in supine position, a sterile needle will be inserted into the latent myofascial trigger point of the extensor digitorum muscle. Once a local twitch response has been obtained, the needle will remain inserted in the trigger point. The metallic tip of the Pointer Plus Excel-II device will be placed in contact with the needle, and a TENS current will be applied for 3 minutes at a frequency of 2 Hz and a pulse width of 220 milliseconds. The intensity will be increased until visible, non-painful contractions of the extensor digitorum muscle are achieved.

Study summary

This randomized single-blind clinical trial aims to compare the effects of different dry needling and electrical dry needling techniques applied to latent myofascial trigger points in the extensor digitorum muscle of the dominant forearm in healthy adults.

Participants will be randomly allocated to one of five groups: a control group, a Hong fast-in and fast-out dry needling group, a rotational dry needling group, a bipolar electrical dry needling group, or a monopolar electrical dry needling group. The main outcomes will be post-needling soreness intensity and duration. Secondary outcomes will include pain during the needling procedure, pressure pain threshold assessed by algometry, handgrip strength, range of motion of finger flexion and wrist palmar flexion, perceived comfort during the intervention, and perceived interference of post-needling soreness with daily activities.

Assessments will be performed at baseline, 5 minutes after the intervention, and at 24, 48, and 72 hours after the intervention.

Eligibility

Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Adults aged 18 to 40 years. * Healthy participants with a latent myofascial trigger point in the extensor digitorum muscle of the dominant forearm. * No pathology affecting the upper limb where the intervention will be applied. * No episode of pain in the upper limb during at least the previous two months. * No contraindications to dry needling or electrical dry needling techniques. * Voluntary signature of the informed consent form. * Willingness to follow the protocol proposed by the research team. Exclusion Criteria: * Needle phobia. * Coagulation disorders. * Pregnancy. * Thyroid disorders. * Altered skin integrity in the treatment area. * Epilepsy. * Local or systemic infection. * Diagnosed neurological disorders affecting pain perception or neuromuscular function in the region of interest, such as multiple sclerosis or peripheral neuropathies. * Generalized chronic pain conditions, such as fibromyalgia. * Weekly use of analgesic medication, including anti-inflammatory drugs, opioids, or other pain-relieving medication.

Primary outcome measure(s)

  • Post-needling soreness intensity — 1 week
    Post-needling soreness intensity will be assessed using a numerical pain rating scale. Participants will rate the intensity of local soreness perceived in the needling area, clearly differentiated from any other type of pain. Higher scores indicate greater pain intensity.

Trial sites (1)

FacilityCityRegionStatus
Facultat de Medicina i Ciències de la Salut Reus Tarragona Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07672093 on ClinicalTrials.gov ↗ ← All trials in Spain